TORNTPHARM Q3 FY25 earnings call.
A source-linked concall view: reported numbers, management language, guidance, commitments and risks that should carry forward.
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Revenue
₹2,809 Cr
verified against source
Revenue YoY
3%
reported change
EBITDA
₹914 Cr
latest reported figure
Source
screener in enriched
record provenance
Actual signal trajectory
Where this quarter sits.
Quarter read
What the record says.
Torrent Pharma delivered Q3 FY25 results with reported revenue of INR 2,809 crores (up 3% YoY) and EBITDA of INR 914 crores (up 5% YoY), with margins sustained at 32.5%. The reported numbers were impacted by two temporary factors: the insulin CMO facility halt (zero revenue this quarter vs. normal INR 75-80 crores quarterly run-rate) and BRL depreciation (17% impact on Brazil top-line). Normalizing for these, underlying revenue grew 7% and EBITDA grew 12%. India business continues to outperform with 12% growth vs. market at 8%, driven by cardiac (16%), diabetes, and gastro divisions. Brazil posted 10% constant currency growth with 14% secondary sales per IQVIA. Management guided 50-100 bps annual margin improvement trajectory and expects to become net cash by H1 FY27. Key strategic priorities include GLP-1 launches in India and Brazil (targeting day-one presence) and continued field force expansion (6,200 MRs). Risk factors include BRL depreciation headwinds persisting for another 1-2 quarters, U.S. generics pressure from aging ANDAs, and uncertain GLP-1 market formation in India given potential price gaps versus existing OAD therapies.
Colored figures show movement against the previous available record.
Guidance to track
- Management expects EBITDA margins to expand 50-100 basis points per year going forward. FY25 full-year margin expected at ~32.5% vs 31.4% in FY24, implying ~110bps improvement this year.
- Company expects to become net cash by first half of FY2027 as debt repayments continue. Interest expenses will decline quarter-on-quarter as repayments progress.
- Management confirmed intent to launch GLP-1 products on day one of market opening in both India (March 2026) and Brazil (January 2026). For injectables, manufacturing will be partnered; oral GLP-1 will be in-house.
- Annual government-mandated price revisions in Brazil expected to be closer to double-digit (vs mid-single digit in last 3-4 years), providing price compensation starting April 2026.
Risks flagged
- BRL depreciated 17% this quarter, causing ~2% impact on consolidated revenue. Management expects this headwind to continue for another 1-2 quarters, affecting near-term reported growth.
- U.S. revenues stable at $32M but facing headwinds from price erosion on existing ANDAs. New filings are low single-digit, making meaningful recovery unlikely in near term. EIR with VAI classification received for Pithampur facility.
- Analyst raised concern about price gap between GLP-1 injectables (estimated INR 500+/month) vs generic OADs like sitagliptin (INR 150/month), questioning demand uptake. Management acknowledged demand uncertainty and noted 5x price gap could limit addressable market despite diabetes-obesity combination potential.
- Market IPM volume growth near zero despite 12% Torrent India growth. Analyst asked why muted volume trends persist; management cited difficulty in explaining market-wide phenomenon but noted their chronic-focused segments haven't seen similar impact.
Key quotes
- Our plan is to be there on day one of launch in GLP-1. Cannot comment on anything further at this stage, but that's certainly the endeavor. That's for India and for Brazil.
- I don't know about 5x, but certainly there will be a gap between the existing products on the market, the tablets especially, and the injections, for example, in GLP-1. So that obviously reduces your addressable market overall, though it's still a large-sized market when you look at diabetes plus obesity put together.
- I'm optimistic on Brazil, and I'm not as optimistic on India. So hopefully.
Research modules